Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37574821

Phase II study of (131) I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Pediatr Blood Cancer
Publication date
2023 Nov
First author
Sevrin F

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Sevrin F
      type
      Author
    2. name
      Kolesnikov-Gauthier H
      type
      Author
    3. name
      Cougnenc O
      type
      Author
    4. name
      Bogart E
      type
      Author
    5. name
      Schleiermacher G
      type
      Author
    6. name
      Courbon F
      type
      Author
    7. name
      Gambart M
      type
      Author
    8. name
      Giraudet AL
      type
      Author
    9. name
      Corradini N
      type
      Author
    10. name
      Badel JN
      type
      Author
    11. name
      Rault E
      type
      Author
    12. name
      Oudoux A
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Sevrin F
      type
      Author
    2. name
      Kolesnikov-Gauthier H
      type
      Author
    3. name
      Cougnenc O
      type
      Author
    4. name
      Bogart E
      type
      Author
    5. name
      Schleiermacher G
      type
      Author
    6. name
      Courbon F
      type
      Author
    7. name
      Gambart M
      type
      Author
    8. name
      Giraudet AL
      type
      Author
    9. name
      Corradini N
      type
      Author
    10. name
      Badel JN
      type
      Author
    11. name
      Rault E
      type
      Author
    12. name
      Oudoux A
      type
      Author
    bibliography ids
    1. nci-bib-74a48056ad7039bc53405aed
    book metadata
    content sha256
    319a5c75acb28235b5134c026274fbadc680e4b5a34a700853aaeb60e1ddeefc
    document type
    citation
    dois
    1. 10.1002/pbc.30615
    electronic publication date
    display
    2023 Aug 13
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37574821
    immutable id
    pubmed:37574821@319a5c75acb28235b5134c026274fbadc680e4b5a34a700853aaeb60e1ddeefc
    journal
    abbreviation
    Pediatr Blood Cancer
    issn electronic
    1545-5017
    issn print
    1545-5009
    issue
    11
    name
    Pediatric blood & cancer
    nlm unique id
    101186624
    pages
    e30615
    volume
    70
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37574821
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      14a5db476c2fd13e2af19c64135486eea5429e291e17cf891614de76c1ff6ad6
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 Nov
      precision
      month
      year
      2023
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37574821/
      title
      Phase II study of (131) I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP.

      Preserved source evidence · Not medical advice